Risk factors and management of osteoporosis in inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 30, Issue 2, 2014, Pages 168-174

  Targownik, Laura E ^a   Bernstein, Charles N ^a   Leslie, William D ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Bone mineral density; Crohn's disease; Inflammatory bowel disease; Osteoporosis; Ulcerative colitis

Indexed keywords

BONE DENSITY; HUMANS; INFLAMMATORY BOWEL DISEASES; MASS SCREENING; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK FACTORS;

EID: 84894035856     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000037     Document Type: Review

References (96)

1. Bernstein CN, Leslie WD. Review article: Osteoporosis and inflammatory bowel disease. Aliment Pharmacol Ther 2004; 19:941-952
2. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994; 4:368-381
3. Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 417-422
4. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:795-841
5. Pollak RD, Karmeli F, Eliakim R, et al. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998; 93:1483-1490
6. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20:1185-1194
7. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: Scientific review. JAMA 2002; 288:1889-1897
8. Morin S, Lix LM, Azimaee M, et al. Mortality rates after incident nontraumatic fractures in older men and women. Osteoporos Int 2011; 22:2439-2448
9. Bentler SE, Liu L, Obrizan M, et al. The aftermath of hip fracture: Discharge placement, functional status change, and mortality. Am J Epidemiol 2009; 170:1290-1299
10. Schousboe JT, Ensrud KE, Nyman JA, et al. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 2005; 53:1697-1704
11. Schousboe JT, Gourlay ML. Comparative effectiveness and cost-effectiveness of strategies to screen for osteoporosis in postmenopausal women. Ann Intern Med 2011; 155:788-789
12. Barr RJ, Stewart A, Torgerson DJ, Reid DM. Population screening for osteoporosis risk: A randomised control trial of medication use and fracture risk. Osteoporos Int 2010; 21:561-568
13. Kanis JA, Johnell O, De Laet C, et al. A meta-Analysis of previous fracture and subsequent fracture risk. Bone 2004; 35:375-382
14. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767-773
15. Farmer ME, White LR, Brody JA, Bailey KR. Race and sex differences in hip fracture incidence. Am J Public Health 1984; 74:1374-1380
16. Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-Analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet 2012; 44:491-501
17. Rivadeneira F, Styrkarsdottir U, Estrada K, et al. Twenty bone-mineral-density loci identified by large-scale meta-Analysis of genome-wide association studies. Nat Genet 2009; 41:1199-1206
18. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337:670-676
19. Reid IR, Mason B, Horne A, et al. Randomized controlled trial of calcium in healthy older women. Am J Med 2006; 119:777-785
20. Ensrud KE, Cauley J, Lipschutz R, Cummings SR. Weight change and fractures in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1997; 157:857-863
21. Ensrud KE, Lipschutz RC, Cauley JA, et al. Body size and hip fracture risk in older women: A prospective study. Study of Osteoporotic Fractures Research Group. Am J Med 1997; 103:274-280
22. Recker R, Lappe J, Davies K, Heaney R. Characterization of perimenopausal bone loss: A prospective study. J Bone Miner Res 2000; 15:1965-1973
23. Greenspan SL, Coates P, Sereika SM, et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90:6410-6417
24. Kroger H, Honkanen R, Saarikoski S, Alhava E. Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis-A population based study. Ann Rheum DisV 53 1994; 18-23
25. Kemppainen T, Kroger H, Janatuinen E, et al. Osteoporosis in adult patients with celiac disease. Bone 1999; 24:249-255
26. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125:941-966
27. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36:1115-1121
28. Svare A, Nilsen TI, Bjoro T, et al. Hyperthyroid levels of TSH correlate with low bone mineral density: The HUNT 2 study. Eur J Endocrinol 2009; 161:779-786
29. Howe TE, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2011; 3:; CD000333
30. Marshall D, Johnell O, Wedel H. Meta-Analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312:1254-1259
31. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341:72-75
32. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007; 18:1033-1046
33. Tinetti ME, Doucette J, Claus E, Marottoli R. Risk factors for serious injury during falls by older persons in the community. J Am Geriatr Soc 1995; 43:1214-1221
34. van Hogezand RA, Hamdy NA. Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl 2006; 243:59-64
35. Cauley JA, Danielson ME, Boudreau RM, et al. Inflammatory markers and incident fracture risk in older men and women: The Health Aging and Body Composition Study. J Bone Miner Res 2007; 22:1088-1095
36. Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immun Rev 2005; 208:207-227
37. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490-495
38. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008; 473:139-146
39. Tilg H, Moschen AR, Kaser A, et al. Gut, inflammation and osteoporosis: Basic and clinical concepts. Gut 2008; 57:684-694
40. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 1990; 112:352-364
41. Veerappan SG, O'Morain CA, Daly JS, Ryan BM. Review article: The effects of antitumour necrosis factor-Alpha on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33:1261-1272
42. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994; 107:1031-1039
43. Targownik LE, Bernstein CN, Nugent Z, Leslie WD. Inflammatory bowel disease has a small effect on bone mineral density and risk for osteoporosis. Clin Gastroenterol Hepatol 2013; 11:278-285
44. van Staa TP, Cooper C, Brusse LS, et al. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003; 125:1591-1597
45. Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: A population based cohort study. Gut 2004; 53:251-255
46. Targownik LE, Bernstein CN, Nugent Z, et al. Inflammatory bowel disease and the risk of fracture after controlling for FRAX. J Bone Miner Res 2013; 28:1007-1013
47. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: A population based study. Gut 1997; 40:313-319
48. Bernstein CN, Seeger LL, Sayre JW, et al. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10:250-256
49. Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40:228-233
50. Leslie WD, Miller N, Rogala L, Bernstein CN. Body mass and composition affect bone density in recently diagnosed inflammatory bowel disease: The Manitoba IBD Cohort Study. Inflamm Bowel Dis 2009; 15:39-46
51. Bryant RV, Trott MJ, Bartholomeusz FD, Andrews JM. Systematic review: Body composition in adults with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38:213-225
52. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133:795-799
53. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: A nationwide follow-up study of 16 416 patients in Denmark. Am J Epidemiol 2002; 156:1-10
54. Loftus EV Jr, Achenbach SJ, Sandborn WJ, et al. Risk of fracture in ulcerative colitis: A population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol 2003; 1:465-473
55. Krawitt EL, Beeken WL, Janney CD. Calcium absorption in Crohn's disease. Gastroenterology 1976; 71:251-254
56. Poley JR, Hofmann AF. Role of fat maldigestion in pathogenesis of steatorrhea in ileal resection. Fat digestion after two sequential test meals with and without cholestyramine. Gastroenterology 1976; 71:38-44
57. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol 2002; 37:192-199
58. Silvennoinen JA, Karttunen TJ, Niemela SE, et al. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37:71-76
59. van Hogezand RA, Banffer D, Zwinderman AH, et al. Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease. Osteoporos Int 2006; 17:535-542
60. Shen B, Remzi FH, Oikonomou IK, et al. Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-Anal anastomosis. Am J Gastroenterol 2009; 104:639-646
61. Navaneethan U, Shen L, Venkatesh PG, et al. Influence of ileal pouch anal anastomosis on bone loss in ulcerative colitis patients. J Crohn Colitis 2011; 5:415-422
62. Kuchuk NO, van Schoor NM, Pluijm SM, et al. Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: Global perspective. J Bone Miner Res 2009; 24:693-701
63. Cauley JA, Lacroix AZ, WuL, et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 2008; 149:242-250
64. Bours PH, Wielders JP, Vermeijden JR, van De Wiel A. Seasonal variation of serum 25-hydroxyvitamin D levels in adult patients with inflammatory bowel disease. Osteoporos Int 2011; 22:2857-2867
65. Vagianos K, Bector S, McConnell J, Bernstein CN. Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr 2007; 31:311-319
66. Driscoll RH Jr, Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology 1982; 83:1252-1258
67. Bernstein CN, Bector S, Leslie WD. Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease. Am J Gastroenterol 2003; 98:2468-2473
68. Leslie WD, Miller N, Rogala L, Bernstein CN. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: The Manitoba IBD Cohort Study. Am J Gastroenterol 2008; 103:1451-1459
69. van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006; 79:129-137
70. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroidinduced osteoporosis: A meta-Analysis. Osteoporos Int 2002; 13:777-787
71. Cino M, Greenberg GR. Bone mineral density in Crohn's disease: A longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol 2002; 97:915-921
72. Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol 2005; 3:113-121
73. Kanis JA, Johansson H, Oden A, et al. A meta-Analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19:893-899
74. Targownik LE, Singh H, Nugent Z, Bernstein CN. Prescription drug use in IBD: A population based study. Gastroenterology 2011; 140 (5S1):S778-S779
75. Bernstein CN, Blanchard JF, Metge C, Yogendran M. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol 2003; 98:1797-1801
76. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: Systematic review and meta-Analysis. Am J Gastroenterol 2011; 106:590-599; quiz 600
77. Abourazzak FE, Allali F, Rostom S, et al. Factors influencing quality of life in Moroccan postmenopausal women with osteoporotic vertebral fracture assessed by ECOS 16 questionnaire. Health Qual Life Outcomes 2009; 7:23
78. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Bone mineral density in patients with inflammatory bowel disease: A population-based prospective two-year follow-up study. Scand J Gastroenterol 2004; 39:145-153
79. Targownik LE, Leslie WD, Carr R, et al. Longitudinal change in bone mineral density in a population-based cohort of patients with inflammatory bowel disease. Calcif Tissue Int 2012; 91:356-363
80. Schmidt S, Mellstrom D, Norjavaara E, et al. Low bone mineral density in children and adolescents with inflammatory bowel disease: A populationbased study from Western Sweden. Inflamm Bowel Dis 2009; 15:1844-1850
81. Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary. CMAJ 2010; 182:1864-1873
82. Compston J, Cooper A, Cooper C, et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009; 62:105-108
83. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington D.C: National Osteoporosis Foundation; 2008
84. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19:385-397
85. Kanis JA, McCloskey E, Johansson H, et al. FRAX((R)) with and without bone mineral density. Calcif Tissue Int 2012; 90:1-13
86. Goodhand JR, Kamperidis N, Nguyen H, et al. Application of the WHO fracture risk assessment tool (FRAX) to predict need for DEXA scanning and treatment in patients with inflammatory bowel disease at risk of osteoporosis. Aliment Pharmacol Ther 2011; 33:551-558
87. Institue of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. 2011; http://books.nap.edu/openbook.php?record-id=13050. [Accessed on 24 December 2013]
88. Kornbluth A, Hayes M, Feldman S, et al. Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria. Am J Gastroenterol 2006; 101:1546-1550
89. Pickhardt PJ, Pooler BD, Lauder T, et al. Opportunistic screening for osteoporosis using abdominal computed tomography scans obtained for other indications. Ann Intern Med 2013; 158:588-595
90. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383-1395
91. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37:674-678
92. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002; 359:1541-1549
93. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62:1515-1526
94. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339:292-299
95. Melek J, Sakuraba A. Efficacy and safety of medical therapy for low bonemineral density in patients with inflammatory bowel disease: A meta-Analysis and systematic review. Clin Gastroenterol Hepatol 2014; 12:32-44.e5
96. Rizzoli R, Reginster JY, Boonen S, et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 2011; 89:91-104